Jazz Pharmaceuticals shared on LinkedIn:
“In HER2-positive gastric and gastroesophageal cancer, first-line therapy is a foundation. The decisions made at the start of treatment determine what is possible for patients from that point forward.
Yesterday’s U.S. FDA approval of a new first-line option helps physicians at the point in treatment where it can translate early advances into meaningful benefit for patients.
Chumi Khurana, Senior Vice President and Oncology Franchise Head, shared her perspective on what this milestone means for patients in the oncology community.”
Chumi Khurana, Senior Vice President US Oncology shared a post on LiknedIn by Jazz Pharmaceuticals, adding:
“In Oncology, progress can be tangible, yet in certain areas the urgency to push further is undeniable. HER2 Positive Gastroesophageal Adenocarcinoma (GEA) has always been one of those areas.
Getting innovation to patients at the start of treatment has always been the focus. This Jazz approval in GEA reflects years of work toward exactly that.
We are proud of the teams who made this possible and grateful to the patients and families whose trust and participation brought us here.”
Other articles about Jazz Pharmaceuticals on OncoDaily.